Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza.
Abbott TR, Dhamdhere G, Liu Y, Lin X, Goudy L, Zeng L, Chemparathy A, Chmura S, Heaton NS, Debs R, Pande T, Endy D, La Russa MF, Lewis DB, Qi LS
Cell. 2020 May 14;181(4):865-876.e12. doi: 10.1016/j.cell.2020.04.020. Epub 2020 Apr 29.
(Link opens in a new window)
PubMed
(Link opens in a new window)
Article
Plasmids from Article
| ID | Plasmid | Purpose |
|---|---|---|
| 155303 | pSLQ5079_pHR_PGK_sfGFP_CoV-F1 | SARS-CoV-2 fluorescent reporter 1 |
| 155304 | pSLQ5080_pHR_PGK_sfGFP_CoV-F2 | SARS-CoV-2 fluorescent reporter 2 |
| 155305 | pSLQ5428_pHR_EF1a-mCherry-P2A-Rfx_Cas13d-2xNLS-3xFLAG | Lentiviral vector encoding Rfx Cas13d fused with 2xNLS, 3xFLAG, and 2A-tagged mCherry. |
| 155306 | pSLQ5429_pUC_hU6-crScaffold_EF1a-BFP | Rfx Cas13d guide cloning pUC19 vector with constitutively expressed tagBFP |
| 155307 | pSLQ5465_pHR_hU6-crScaffold_EF1a-PuroR-T2A-BFP | Rfx Cas13d guide cloning lentiviral vector with constitutively expressed puromycin resistance 2A-tagged with tagBFP |